{"id":"transient-continuous-subcutaneous-insulin-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infusion set occlusion"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a delivery system technology rather than a novel molecular entity. It administers insulin through periodic subcutaneous infusions, designed to mimic physiological insulin secretion patterns more closely than conventional insulin injection regimens. The transient nature suggests intermittent rather than continuous delivery, potentially reducing hypoglycemia risk while maintaining glycemic control.","oneSentence":"Transient continuous subcutaneous insulin infusion delivers insulin intermittently via subcutaneous infusion to improve glycemic control in diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:13:47.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus requiring insulin therapy"}]},"trialDetails":[{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01574508","phase":"PHASE4","title":"Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-12","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT01277965","phase":"NA","title":"Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity","status":"COMPLETED","sponsor":"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète","startDate":"2010-03","conditions":"Type 1 Diabetes With a Subcutaneous Insulin Pump, Adjustment of the Recommended Basal Insulin Flow Rate in the Event of Physical Activity, Adjustment of the Recommended Prandial Insulin in the Event of Physical Activity","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CSII"],"phase":"marketed","status":"active","brandName":"Transient Continuous Subcutaneous Insulin Infusion","genericName":"Transient Continuous Subcutaneous Insulin Infusion","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Transient continuous subcutaneous insulin infusion delivers insulin intermittently via subcutaneous infusion to improve glycemic control in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}